Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a strong-buy rating in a report released on Tuesday morning. The firm currently has $7.75 target price on the biotechnology company’s stock.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a buy rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 13th. They noted that the move was a valuation call. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a hold rating to a buy rating in a report on Friday, August 10th. Jefferies Financial Group reiterated a buy rating and issued a $8.50 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, August 9th. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, August 8th. Finally, Royal Bank of Canada reiterated a buy rating and issued a $9.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 7th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. BioCryst Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $9.89.
BCRX opened at $7.01 on Tuesday. BioCryst Pharmaceuticals has a 52-week low of $4.12 and a 52-week high of $8.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. The stock has a market cap of $834.59 million, a PE ratio of -8.99 and a beta of 1.64.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.05. BioCryst Pharmaceuticals had a negative net margin of 270.95% and a negative return on equity of 107.85%. The company had revenue of $12.49 million for the quarter, compared to the consensus estimate of $3.80 million. On average, analysts anticipate that BioCryst Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 9,850 shares of the company’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the sale, the insider now owns 140,633 shares in the company, valued at approximately $1,018,182.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO William P. Sheridan sold 62,500 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $7.03, for a total value of $439,375.00. Following the completion of the sale, the chief marketing officer now owns 85,713 shares in the company, valued at approximately $602,562.39. The disclosure for this sale can be found here. 5.21% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its position in BioCryst Pharmaceuticals by 1.1% in the 1st quarter. Northern Trust Corp now owns 1,188,876 shares of the biotechnology company’s stock worth $5,671,000 after purchasing an additional 13,044 shares in the last quarter. Wells Fargo & Company MN boosted its position in BioCryst Pharmaceuticals by 29.3% in the 1st quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 15,403 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in BioCryst Pharmaceuticals by 5.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 519,060 shares of the biotechnology company’s stock worth $2,975,000 after purchasing an additional 28,084 shares in the last quarter. Paloma Partners Management Co purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth approximately $174,000. Finally, State of Wisconsin Investment Board boosted its position in BioCryst Pharmaceuticals by 79.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 44,300 shares in the last quarter. Institutional investors and hedge funds own 80.23% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
See Also: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.